Revvity Htrf Human C1q Binding Kit

Revvity Complement-Dependent Cytotoxicity (CDC) is an important effector function of antibodies. Activation of the classical complement pathway is initiated by the binding of the complement protein C1q to the Fc region of immunoglobulins bound to a cell surface target antigen. This interaction triggers the sequential enzymatic activation of circulating complement proteins, and finally leads to the formation of the Membrane Attack Complex (MAC) that mediates target cell lysis. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity The capacity of C1q binding and resultant CDC activity can influence the safety and efficacy of therapeutic monoclonal antibodies, and therefore requires characterization during the development process. Engineering the Fc region of IgG antibodies (e.g. by mutations or glycoengineering) is currently an active area of investigation to enhance or reduce the ability of biologics to recruit complement. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity The human C1q binding kit measures the binding of the Fc region of aggregated IgG antibodies to human C1q in solution. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)